CTI-1601
CLIN-1601-101
Phase 2 mab active
Quick answer
CTI-1601 for Friedreich Ataxia is a Phase 2 program (mab) at Larimar Therapeutics with 4 ClinicalTrials.gov record(s).
Program details
- Company
- Larimar Therapeutics
- Indication
- Friedreich Ataxia
- Phase
- Phase 2
- Modality
- mab
- Status
- active